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In this chapter, we compare the challenges and best practices identified in the country 
chapters so that the in-depth analysis of selected Member States is complemented 
with a broader overview . In doing so, we aim to provide a better understanding of 
the practical implementation of the new European Union (EU) pharmacovigilance 
legislation across Member States .
The chapter is structured as follows . First, the national pharmacovigilance sys-
tems are compared regarding their structural factors as well as their institutional 
frameworks . The second section deals with the main finding of this study, namely 
the underreporting of adverse drug reactions (ADRs) in the Member States . This 
finding is substantiated by identifying problems in terms of batch numbers for bio-
logical medicinal products (biologicals), scientific evaluation, signal detection and 
information processing . Finally, we present a comparison of factors contributing 
to underreporting . The key factors in this respect are as follows:
•	 Lack of awareness
•	 Complexity of ADR reporting
•	 Lack of cooperation
•	 Interconnectivity problems
Key factors and the underlying reasons have been discovered through repeated 
rounds of trial and error, relying on pharmacovigilance literature, reports on the 
effectiveness of pharmacovigilance systems and interview data gathered for the 
selected cases . By probing the empirical evidence with a variety of categorisations, 
we aimed to find the right balance in the accurate reporting of specific reasons while 
relying on key factors for meaningful comparative analysis and generalisation .
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6.1 Pharmacovigilance Systems
6.1 Pharmacovigilance Systems
The objective of this section is to provide a comparative overview of the national 
pharmacovigilance systems . As indicated in Chapter 3, EU pharmacovigilance is 
a multi-level system where actors are linked through multiple inter-institutional 
relations . Adding to this complexity, national pharmacovigilance systems them-
selves comprise a multitude of actors, which cooperate in line with patterns of 
implementation (see Chapter 5) .
Level of Centralisation
Due to different healthcare policies and institutions, there is considerable varia-
tion in the level of centralisation . Whereas some Member States have centralised 
systems of pharmacovigilance, others have decentralised systems . Germany, the 
United Kingdom, Finland and Poland have centralised systems; Portugal and 
France have decentralised systems . The decentralised systems are characterised 
by having regional centres for collecting and processing pharmacovigilance data .
The level of centralisation, however, is not set in stone . Whereas Portugal has 
moved from a centralised system to a decentralised system in the early 2000s, the 
United Kingdom has set up regional Yellow Card centres .
Although the system in Germany is centralised, sectoral associations of physicians 
and pharmacists provide functional links between patients, healthcare providers and 
national competent authorities . Hence, the system can be characterised as highly 
complex . Depending on the type of medicine, two different national agencies are 
at the centre of ADR reporting .
Supervision
In terms of supervision, the national agencies implementing pharmacovigilance are 
usually supervised by the health and social security ministries . In implementing 
pharmacovigilance, the agencies are also accountable to respective ministries . In 
the sample, however, Finland and Poland are exceptions . Even though Fimea and 
URPL are officially headed by ministries that set the legal guidelines, they are de 
facto independent and do not have to justify their decisions .
Separate Systems for Biologicals
There is considerable variation among Member States regarding the classification of 
biologicals . Whereas some Member States operate separate systems for biologicals, 
others treat biologicals as part of their general pharmacovigilance systems . In the 
sample, only Germany operates a separate system for biologicals . In line with its 
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complex system, there are two national agencies operating in Germany, one dealing 
with synthetic medicines and the other one with biologicals . Finland and Poland 
have a system for biological vaccines . However, Portugal, France and the United 
Kingdom have no separate system .7
This variation is not surprising, given the fact that there is no unambiguous 
agreement among Member States about how to classify biologicals (see Klein et 
al . 2015) .
Legal Requirements
In the sample, almost all Member States have legal requirements for healthcare 
professionals to report ADRs, i .e . Portugal, France, Finland and Poland . In France, 
this includes brand names and batch numbers of biologicals (Vermeer et al . 2015: 
8) . In Germany and the United Kingdom, there are no legal requirements in place, 
and hence ADR reporting in these countries is based on professional obligations 
and codes of conduct . In Poland, there are legal requirements but no punishment 
in the case of non-compliance .
Patients are generally not required to report ADRs, in contrast to marketing 
authorisation holders that are legally obligated to report them in all countries 
under investigation .
Prescribing Medicines
There is also considerable variation among Member States regarding the practice 
of prescribing medicines . In line with the different national health systems, doctors 
and pharmacists might substitute different medicines with the same active sub-
stance . Previous studies have shown that prescribers often communicate only the 
international non-proprietary name (INN) in ADR reporting (Dolinar and Reilly 
2014) . Merely indicating the INN in an ADR report can be misleading, though, as 
two different medicines (the original biological and the new biosimilar) may have 
the same non-proprietary scientific name . However, while some stakeholders call 
for a change to such practices, the majority of Member States maintain that bio-
similars and reference products should be closely aligned and that using different 
INNs undermines such an alignment (see European Commission Pharmaceutical 
Committee 2013) .
7 Despite the absence of a separate system, biologicals receive particular attention in the 
United Kingdom . Biologicals are discussed by MHRA experts in separate meetings .


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The objective of this section is to present underreporting as the main finding of 
this study .
Underreporting
The most important challenge for the effective implementation of Directive 2010/84/
EU is the underreporting of ADRs . In all Member States in the sample, respondents 
highlight this (the United Kingdom, Poland, France, Portugal and Germany) . This 
study thereby confirms previous studies based on the comparative analysis of cases 
selected on their variation in terms of national health systems .
This is remarkable, given that in 22 countries (79 percent) reporting of ADRs 
is a legal obligation for healthcare professionals, and the percentage of countries 
with mandatory reporting of ADRs for vaccines is even higher, i .e . 26 countries 
(89 percent) (Šarinić et al . 2016) .
The highest percentage (38 percent) of all ADR reports is received via web-
based applications, even though the number of Member States having web-based 
reporting is lower than the number of Member States with mail-reporting channels 
available (21 vs . 28, respectively) (Šarinić et al . 2016) . In our sample, only a minority 
of the French regional pharmacovigilance centres appeared to have websites and 
thereby web-based reporting formats . In Finland, even though online reporting is 
possible for physicians and pharmacists, patients have to resort to regular mail . All 
Member States have ADR reporting forms available on their national competent 
authorities’ websites (SCOPE) .
There are two important aspects to underreporting: the quantity and quality 
of information . Quantity refers to the number of ADR reports; quality refers to 
the value of information . Both dimensions are sometimes mutually exclusive, 
as increases in quantity might lead to decreases in quality . Whereas quantity of 
information is important, an appropriate level of quality is essential for effective 
pharmacovigilance . Some respondents fret about incomplete reports, requiring fol-
low-up and thereby further increasing the workload (Germany) . Other respondents 
were rather satisfied with the quality of ADR reports but criticized the number of 
reports submitted (Poland) .
Information Overload
Furthermore, information overload can make it difficult to detect signals (Germany) . 
This problem is exacerbated by the fact that the legislation allows the collection of 
information from all possible and available sources such as patients and literature 
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reports . This also leads to an increased pool of information from which relevant 
signals can be analysed (Borg et al . 2015: 121) .
There is considerable variation in the Member States regarding evaluation and 
signal detection .
In the United Kingdom, there is no evaluation of reports before signal detection; 
due to the large quantity of information, signal detection has been automated . After 
prioritising detected signals, the national competent authority, the Medicines and 
Healthcare Products Regulatory Agency (MHRA), forwards serious cases to EMA .
Causality Assessments
In the two decentralised systems, Portugal and France, ADR reports are collected 
and evaluated by the regional units . However, problems in terms of quantity and 
quality might lead to problems in terms of causality assessments (France) . After 
the evaluation, including the causality assessment, the reports are forwarded to 
the national competent authorities . Reports by marketing authorisation holders 
are forwarded directly to the national agencies .
Traceability of Biologicals
Previous studies showed that the reporting of batch numbers and traceability of 
biologicals is subject to considerable variation among Member States (Vermeer et 
al . 2015; see also European Commission 2015) . Various studies on ADR reporting 
revealed that batch numbers were available for only a limited number of suspected 
biologicals (Vermeer et al . 2013: 620-621; see also Vermeer et al . 2015: 6) .
Again, this study substantiates this . Respondents in various Member States in 
the sample confirm that reporting batch numbers remains a challenge (the United 
Kingdom) . Batch numbers are reported infrequently (France) or not at all (Poland) . 
Only in Finland did the reporting of batch numbers satisfy the respondents which 
has been corroborated by Fimea’s statistics .
Strengthening Patient Involvement
One of the aims of Directive 2010/84/EU is to strengthen patient involvement in 
the safety monitoring of medicines . All 28 Member States have patient reporting 
systems in place, with the majority initiating them in 2012-2013 (although the 
first Member States to introduce this process did so only starting in 1968 and 
the second time in 1996) . Overall, the number of individual patient reports from 
the European Economic Area has increased over the two and a half years of the 
reporting period by around 50 percent . This includes ADR reports not submitted 
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by other reporters such as healthcare professionals, which represent information 
that would not otherwise be captured (Commission 2016) .
However, reporting ADRs regarding biologicals and respective traceability re-
mains a challenge when it comes to patient reporting . For instance, batch numbers 
have to be displayed on each package in the United Kingdom, but patients often do 
not have access to the package when the drug is administered in a hospital setting .
6.3 Comparison of Factors Contributing to 
Underreporting
6.3 Comparison of Factors Contributing to Underreporting
The objective of this section is to compare factors contributing to underreporting 
and thereby to put into comparative perspective the challenges and best practices 
in national pharmacovigilance systems .
6.3.1 Lack of Awareness
As described above, awareness as an analytical category for comparison includes 
a number of factors, such as not only the general awareness of the obligation to 
report, but also indifference regarding the importance of ADR reporting .
Member States have focused on informing healthcare professionals and patients 
about the importance of ADR reporting, particularly regarding biologicals (see 
Vermeer et al . 2015) . The importance of raising awareness has been emphasized as 
part of the SCOPE implementation project (Jadeja and Barrow 2016: 59) .
However, the study reveals that lack of awareness is a prevalent feature in all 
the Member States of our sample (the United Kingdom, Finland, Poland, France, 
Portugal and Germany) . Yet lacking awareness concerns healthcare professionals 
and patients in varying degrees . Whereas in Finland, most healthcare profession-
als are aware of their obligation to report ADRs, the level of public awareness is 
particularly low . Similarly, in the United Kingdom about 80 percent of healthcare 
professionals know about the Yellow Card Scheme, while only 10 percent of patients 
had heard about this .
Lack of Awareness Regarding Biologicals
In some Member States, lack of awareness regarding biologicals seems to be partic-
ularly severe (Poland, Portugal) . This is an interesting finding because Portugal’s 
decentralised system seems well-equipped regarding a key recommendation about 
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the role of regional pharmacovigilance centres for awareness-raising campaigns 
(Jadeja and Barrow 2016: 59-60) . Also, Poland revealed that problems regarding 
ADR reporting of biologicals mainly stemmed from its inexperience and thus its 
unawareness in the field .
Legal Framework
As explained in the fundamentals regarding pharmacovigilance (see Chapter 2), 
legal ramifications of ADR reporting due to liability claims is a specific factor of 
awareness . While healthcare professionals are bound by the legal systems in which 
they operate, awareness regarding the legal ramifications and how they affect ADR 
reporting is a key recommendation (see Chapter 7) .
In general, the possibility of liability claims presents an important impediment 
for ADR reporting . The SCOPE data demonstrates that the quantity can be enhanced 
by exempting healthcare professionals from liability when they report ADRs that 
possibly resulted from medication errors (Šarinić et al . 2016: 218) . In this context, 
our study reveals that liability claims are feared by healthcare professionals in 
Poland, France and Portugal, which impedes ADR reporting in these countries .
In a similar vein, ADRs and the reporting thereof are sometimes perceived as a 
failure of healthcare professionals associated with a threat to professional reputation .
6.3.2 Complexity of ADR Reporting
Complexity as an analytical category encompasses a number of factors related to the 
task of ADR reporting, including not only reporting logistics, but also constraints 
in the work environment of healthcare professionals .
In our study, factors impeding ADR reporting due to complexity have been 
frequently highlighted by respondents and it appears that such complexity affects 
both the quantity and quality of ADR reporting .
For instance, in Finland only healthcare professionals (physicians and pharma-
cists) are able to report online, while patients and nurses have to report through 
regular mail . In Germany, duplications are difficult to filter out because strict data 
protection laws make it difficult to connect databases .
SCOPE data reveals that offering background and supplementary information 
within the electronic or the paper version of the reporting form enhances the qual-
ity of the submitted reports (Jan and Radecka 2015: 63-64) . However, a number of 
respondents, especially in Poland, France and Portugal, cite high workload as an 
impediment to more effective pharmacovigilance .
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ADR reporting is also perceived as time-consuming and complex (France, Portu-
gal) . The necessity of having to be available for follow-up questions further disincen-
tives healthcare professionals, given that reporting is not a one-off activity, but may 
turn into a lengthy process . This also has negative consequences for data quantity .
Training in Pharmacovigilance
The lack of quality (and also underreporting and the lack of quantity) are related 
to the neglect of pharmacovigilance training during medical and pharmaceutical 
education . This is the case in the United Kingdom and Germany . Finland, however, 
offers a very elaborate educational system for healthcare professionals regarding 
pharmacovigilance, and France is one of the first Member States to introduce a 
master’s programme in pharmacovigilance .
The SCOPE data shows that only a minority of the national competent author-
ities (e .g . the MHRA) offer e-learning tools and online educational materials for 
healthcare professionals, although these tools are very efficient and considerably 
improve professional training (Jadeja and Barrow 2016: 57) . Yet in order to imple-
ment legal provisions of EU pharmacovigilance to full effect, training is essential 
for internalising practices that are conducive to the realisation of these provisions . 
Because most ADRs are well-known effects of old drugs, harm might be avoided if 
healthcare professionals (and also patients) were better trained or at least informed 
(Moore and Begaud 2010) .
In general, national pharmacovigilance systems must be seen as dependent on 
general policy developments . In the current political climate, one such development 
is the structural scarcity of funding for regulatory activity .
Financial Resources
Pharmacovigilance is no exception here, with several Member States in the sample 
having to fulfil their functions with limited financial resources (e .g . France, Ger-
many) . While scarce finances are an issue across the board, the problem is acute in 
Southern European Member States such as Portugal that were particularly affected 
by the economic crisis .
6.3.3 Lack of Cooperation
Cooperation is an essential analytical category for contextualising individual 
ADR reporting by healthcare professionals in complex national systems of phar-
macovigilance .
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A multitude of actors in national pharmacovigilance systems require cooperation 
among pharmacovigilance-related institutions in order to ensure system effective-
ness . The SCOPE authors recommend fostering the exchange of information and the 
sharing of best practices among the Member States and the relevant stakeholders 
(Jadeja and Barrow 2016: 58) . Aside from interconnecting state authorities, the 
SCOPE authors also suggest enhancing collaboration with patient organisations 
and professional associations on a national as well as an international level (Jadeja 
and Barrow 2016: 58) .
However, there is considerable variation in the Member States due to their in-
stitutional differences . At one end of the spectrum is Portugal with the successful 
cooperation of agencies, healthcare professionals and universities . At the other end 
of the spectrum is Poland with no cooperation between relevant actors .
6.3.4 Interconnectivity Problems
Due to the increase of ADR reporting since the adoption of Directive 2010/84/EU, 
the technical infrastructure for data processing and interconnectivity of databanks 
is a particular challenge . In order to cope with increasing data, Member States have 
introduced new functionalities to reporting systems and cooperation between 
hospital and pharmacy IT systems (Vermeer et al . 2015: 8) .
SCOPE data suggests that sound and uniform IT systems for reporting ADRs 
on a national as well as an international level would lead to increased efficiency, 
better data quality and error prevention (Šarinić et al . 2016: 220) .
However, the case studies highlight specific problems in terms of interconnec-
tivity . Our study shows that different IT systems and separated online portals are 
seen as impeding interconnectivity in a number of Member States (the United 
Kingdom, France and Germany) .
In conclusion, it is important to emphasize that healthcare policies of Member 
States differ considerably . Accordingly, a comparison of challenges and best prac-
tices can inform mutual learning, yet such learning is contingent on deep-seated 
structural and cultural factors that affect the national implementation of EU 
pharmacovigilance legislation .
Furthermore, broader policy developments have significant effects on the 
implementation of pharmacovigilance . For instance, due to strict data protection 
laws, Germany can be characterised as a laggard in pharmacovigilance research 
(see Douros et al . 2016) . Due to the Mediator scandal, France has to be mentioned 
as well, given that the national pharmacovigilance system is still impeded by sys-
tematic difficulties .
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In the final chapter, we suggest several recommendations aiming to cope with these 
persistent challenges in national ADR reporting systems and thereby to improve 
the practical implementation of Directive 2010/84/EU .
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